Atlas Trials

BeBetter Med Inc

15 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch BeBetter Med Inc

RecordFirmDate
A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) (NCT07676175)BeBetter Med Inc2026-07-01
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (NCT07544056)BeBetter Med Inc2026-06-04
A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C） (NCT07368608)BeBetter Med Inc2026-03-01
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV) (NCT07012109)BeBetter Med Inc2025-06-17
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT06792253)BeBetter Med Inc2025-01-06
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations (NCT06514027)BeBetter Med Inc2024-08-28
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT06164327)BeBetter Med Inc2023-12-01
Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation (NCT06117371)BeBetter Med Inc2023-09-18
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer (NCT06685796)BeBetter Med Inc2023-04-12
Study of Orally Administered BEBT-503 in Healthy Subjects (NCT05391880)BeBetter Med Inc2022-08-26
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy (NCT06998108)BeBetter Med Inc2022-06-09
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer (NCT06706713)BeBetter Med Inc2022-04-15
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects (NCT06074107)BeBetter Med Inc2020-06-12
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer (NCT06047184)BeBetter Med Inc2019-07-15

Track BeBetter Med Inc automatically

Every clearance here is in the API, with alerts when new ones post.